1-6 of 6
Douglas C. Saffran
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 2565: CDK9 inhibitor KB-0742 is active in preclinical models of small-cell lung cancer

Melinda A. Day, Douglas C. Saffran, Tressa Hood, Nikolaus Obholzer, Akanksha Pandey, Charles Y. Lin, Pavan Kumar, Jorge DiMartino
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2565.
https://doi.org/10.1158/1538-7445.AM2022-2565
Published: 15 June 2022
View article titled, Abstract 2565: CDK9 inhibitor KB-0742 is active in preclinical models of small-cell lung cancer
Journal Articles

Abstract 2564: CDK9 inhibition via KB-0742 is a potential strategy to treat transcriptionally addicted cancers

Melinda A. Day, Douglas C. Saffran, Tressa Hood, Nikolaus Obholzer, Akanksha Pandey, Charles Y. Lin, Pavan Kumar, Daniel M. Freed, Jorge DiMartino
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2564.
https://doi.org/10.1158/1538-7445.AM2022-2564
Published: 15 June 2022
View article titled, Abstract 2564: CDK9 inhibition via KB-0742 is a potential strategy to treat transcriptionally addicted cancers
Journal Articles

Abstract 2639: KB-0742 is active in preclinical MYC high models of TNBC, ovarian, and DLBCL cancers

Melinda A. Day, Douglas C. Saffran, Tressa Hood, Nikolaus Obholzer, Akanksha Pandey, Charles Y. Lin, Pavan Kumar, Jorge DiMartino
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2639.
https://doi.org/10.1158/1538-7445.AM2022-2639
Published: 15 June 2022
View article titled, Abstract 2639: KB-0742 is active in preclinical <em>MYC</em> high models of TNBC, ovarian, and DLBCL cancers
Journal Articles

Abstract P5-08-05: Preclinical activity of KB-0742, an oral, highly selective, CDK9 inhibitor, in cell lines and in MYC-high expressing, patient-derived models of multiple breast cancer subtypes

Douglas C. Saffran, Melinda A.L. Day, Nathalie Rioux, Tom Chen, Christina Lee, Suha Naffar-Abu Amara, David B. Freeman, Tressa Hood, Charles Y. Lin, Pavan Kumar, Jorge DiMartino
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-08-05.
https://doi.org/10.1158/1538-7445.SABCS21-P5-08-05
Published: 15 February 2022
View article titled, Abstract P5-08-05: Preclinical activity of KB-0742, an oral, highly selective, CDK9 inhibitor, in cell lines and in MYC-high expressing, patient-derived models of multiple breast cancer subtypes
Journal Articles

Abstract 1141: CDK9 inhibition is selective for transcriptionally addicted tumors harboring MYC genomic amplifications

Melinda A. Day, Nikolaus D. Obholzer, Akanksha Pandey, Tom Chen, Tong Liang, Rosa A. Villagomez, Mulini Pingili, Jost V. Koren, David B. Freeman, Holly M. Nguyen, Jennifer L. Conor, Eva Corey, Matthew G. Reese, Andrew Boghossian, Brienne Engel, Melissa M. Ronan, Jennifer A. Roth, Joesph P. Vacca, Peter B. Rahl, Marius S. Pop, Benjamin W. Trotter, Charles Y. Lin, Jorge C. DiMartino, Pavan Kumar, Douglas C. Saffran
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1141.
https://doi.org/10.1158/1538-7445.AM2021-1141
Published: 01 July 2021
View article titled, Abstract 1141: CDK9 inhibition is selective for transcriptionally addicted tumors harboring <em>MYC</em> genomic amplifications
Journal Articles

Catalytic Cleavage of the Androgen-regulated TMPRSS2 Protease Results in Its Secretion by Prostate and Prostate Cancer Epithelia

Daniel E. H. Afar, Igor Vivanco, Rene S. Hubert, James Kuo, Emily Chen, Douglas C. Saffran, Arthur B. Raitano, Aya Jakobovits
Journal: Cancer Research
Cancer Res (2001) 61 (4): 1686–1692.
Published: 02 February 2001
View article titled, Catalytic Cleavage of the Androgen-regulated TMPRSS2 Protease Results in Its Secretion by Prostate and Prostate Cancer Epithelia
Open the PDF for Catalytic Cleavage of the Androgen-regulated TMPRSS2 Protease Results in Its Secretion by Prostate and Prostate Cancer Epithelia in another window